The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: A phase 1, open-label, single-group trial

The Lancet: Gastroenterology & HepatologyKao D, Wong K, Franz R, et al. | February 25, 2021

Advertisement

Although highly effective for recurrent Clostridioides difficile infection, fecal microbiota transplantation (FMT) has inherent risks. Researchers here evaluated the activity, safety, and tolerability of Microbial Ecosystem Therapeutic 2 (MET-2), an oral encapsulated formulation of 40 lyophilised bacterial species initially isolated from stool of a healthy donor, but manufactured independently of donors. In this phase 1, open-label, single-group feasibility study, they included 19 patients with mild to moderate C difficile infection and at least one episode of recurrence (ie, two episodes of C difficile infection) within 12 months. Participants' initial daily treatment was ten oral capsules for 2 days, then three capsules for 8 days. A higher dose was offered in cases with C difficile infection recurrence: 20 capsules for 2 days, then three capsules for 8 days. MET-2 treatment resulted in significant improvement in quality of life as well as alpha diversity in stool microbial composition. After treatment, most patients exhibited MET-2 associated taxa in greater abundance compared with baseline. By day 130, 16 (84%) of 19 patients did not have recurrence of C difficile infection. Overall findings support the safety, efficacy, and good tolerability of MET-2 among patients with recurrent C difficile infection.

Read the full article on The Lancet: Gastroenterology & Hepatology

Advertisement